期刊文献+

替诺福韦的肾毒性及其遗传药理学研究状况 被引量:7

Rsearch status of tenofovir on renal toxicity and pharmacogenetics
原文传递
导出
摘要 替诺福韦(TFV)是一类抑制HIV-1反转录酶的腺苷磷酸无环核苷类似物,因其高有效性、低毒性及其每天只用服用一次的便利而被广泛使用。然而,该药可引起肾功能损伤。肾功能损伤存在着较高的个体差异,因此越来越多的研究关注于替诺福韦引起的肾损伤与遗传因素的相关性。本文对替诺福韦的肾毒性的相关遗传因素进行综述。 Tenofovir( TFV) is a class of inhibiting HIV-1 reverse transcriptase,adenosine phosphate acyclic nucleoside analogs. Because of its high effectiveness,low toxicity and only be taken once per day,it is widely used nowadays. However,it was reported that the drug can cause kidney damage. Since there is a high individual difference of renal impairment,more and more researches focus on the association of renal injury which caused by TFV and genetic factors. The nephrotoxicity of tenofovir and the genetic factors which may increase renal tubular disease are reviewed in this paper.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2015年第14期1459-1461,1465,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家重大新药创制科技重大专项基金资助项目(2012ZX09303014-001) Supported by International S&T Cooperation Program of China(2014DFA30900)
关键词 替诺福韦 肾毒性 遗传因素 tenofovir nephrotoxicity genetic factors
  • 相关文献

参考文献25

  • 1Murphy MD, O'Hearn M, Chou S, et al. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regi-men containing didanosine[ J]. Clin Infect Dis, 2003, 36 : 1082 - 1085.
  • 2Novoa R, Labarga P, Soriano V. Pharmacogenetics of tenofovir treat- ment [ J ]. Pharrrmcogermmics,2009,10 : 1275 - 1285.
  • 3Hall AM. Update on tenofovir toxicity in the kidney [ J ]. Pediatr Nephrol,2013,28 : 1011 - 1023 .
  • 4Flandre P, Pugliese P, Cuzin Lack I, et al. Risk factors of chronic kidney disease in HIV - infected patients [ J ]. Clin J Am Soc Nephrol,2011,6 : 1700 - 1707.
  • 5Scherzer R, Estrella M, Li Y, et al. Association of tenofovir expo- sure with kidney disease risk in HIV infection[ J ]. AIDS,2012,26: 867 - 875.
  • 6Uwai Y,Ida H,Tsuji Y, et al. Renal transporter of adefovir,eidofo- vir and tenofovir by SLC22A family members( hOATl , bOAT 3 and hOCT 2) [J]. Pharm Res,2007,24:811 -815.
  • 7Imaoka T, Kusuhara H, Adachi M, et al. Function involvement of multidrng resistance - associated protein 4 ( MRP 4/ABCC 4 ) in the renal eliminatin of the antiviral drugs adefovir and tenofovir [ J ]. Mol Ptmrnuao1,2007,71 :619 - 627.
  • 8Jafari A, Khalili H, Dashti -Khavidaki S, et al. Tenofovir- induced nephrotoxicity : incidence, mechanism, risk factors, progno- sis and proposed agents for prevention[J]. Eur J Clin Pharnurol , 2014,70:1029 - 1040.
  • 9Fernandez - Fernandez B, Montoya - Ferret A, Sanz AB, et al. Tcnofovir nephrotoxicity : 2011 update [ J ]. AIDS Res Treat, 2011, 2011 : 354908.
  • 10Cihlar T, Birkus G, Greenwalt D, et al. Tenofovir exhibits low cyto- toxicity in various human cell types:comparison with other nucleo- side reverse transeriptase inhibitors [ J ]. Antiviral Res, 2002,54 : 37 -45.

同被引文献72

  • 1白浪,唐红.HIV感染的抗逆转录病毒治疗[J].四川医学,2005,26(12):1481-1483. 被引量:2
  • 2文爱东,王志睿,杨志福,陈苏宁,冯智军,杨林.富马酸替诺福韦酯胶囊在健康人体内的药动学研究[J].药学服务与研究,2007,7(3):191-193. 被引量:7
  • 3訾梅,蔡皓东,李祥霞.奈韦拉平不良反应文献分析[J].药物流行病学杂志,2007,16(5):284-287. 被引量:9
  • 4郭红英,张继明.替诺福韦酯治疗慢性乙型肝炎的研究进展[J].世界临床药物,2007,28(12):734-737. 被引量:7
  • 5Labarqa P. New update of the DHHS guidelines for adults and chil- dren[J]. AIDS Rev,2015,17(2) : 122.
  • 6Stephan C, Baldauf HM, Barry J, eta./. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients[ J ]. J Antimicrob Chemother ,2014 , 69(10) : 2809-2818.
  • 7Shah BM, Schafer JJ,Priano J,et al. Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection [ J 1. Pharma- cotherapy,2013,33 (10) : 1107-1116.
  • 8Highlights of prescribin8 information. HTTP:// uame. accessdata. fda. gov /drugsatfda_docs /label /2015/203100s016/bl. pdf, 2015- 07-29/2015-09-10.
  • 9Post FA, Winston J, Andrade-Villanueva JF, eta/. Elvitegravir/eo- ]aicistat/emtricitahine/tenofovir d[ in hlv-idected patients with mild- to-modrate renal impairment[ J ]. J Acquir Immune Defic Syndr,2015, 68(3) :310-313.
  • 10Sax PE, Delesus E, Mills A, eta/. Coformulated efavirenz, emtricit- shine, and tenofovir for initial treatment of HIV-1 infection: a ran- domized, double-blind, phase 3 trial, analysis of results after 48 weeks [ J ]. /~ncet, 2012,379 (9835) :2439 -2448.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部